 |
 |
 |
- Dr. Tseng
has obtained the FDA approval and
NIH grant support to conduct Phase I clinical trial to
determine the safety and efficacy of Transplantation
of Ex Vivo Expanded Limbal Epithelial Stem Cells for Treating
Limbal Stem Cell Deficiency.
- Dr. Tseng
received Senior Achievement
Award from American Academy of Ophthalmology during the
annual meeting at New Orleans, LA in 2004.
- Dr. Tseng
gave Kersley Lecture at
the annual meeting of Medical Contact Lens and Ocular Surface
Association (MCLOSA) in London, UK, on Nov 19, 2004 and Oliver
H. Dabezies Jr. M.D. Lecture at the annual meeting of Contact
Lens Association of Ophthalmology (CLAO) in San Diego, CA,
on Jan 22, 2005.
- Dr.
Tseng served as a member of the expert panel for Interagency
Coordinating Committee on Validation of Alternative Methods
(ICCVAM) sponsored by NIH, August 2004 - January 2005.
- Dr. Tseng
has summarized in a recent review explaining
how amniotic membrane works in ocular surface reconstruction.
- Dr. Tseng
and his colleagues have discovered several new applications
of amniotic membrane
transplantation. Amniotic membrane can help both
the donor and recipient eyes receiving conjunctival limbal
autograft and restore deep fornix during symblepharon lysis
(especially in conjunction with intraoperative application
of mitomycin C).
- Dr. Tseng
and his colleagues have discovered that conjunctivochalasis-induced
dry eye an be differentiated from aqueous tear deficiency-induced
dry eye, and that lipid tear deficiency due to meibomian gland
dysfunction is the dominant cause for persistent dry eye following
LASIK using kinetic
analysis of tear interference images.
- Dr. Tseng has been nominated as the regular
member of the Study Section VISA by National Eye Institute, National
Institute of Health
- The Impression
Cytology Laboratory of the Ocular Surface Center is the first
in USA that has been certified by the State of Florida (No. 800017632)
and CLIA (Clinical Laboratory Improvement Amendment 1998) (No.10D1004176)
for diagnosing ocular surface failure in patients suffering difficult
ocular surface diseases.
- Dr. Tseng is licensed to compound special
medications for patients suffering from severe dry eye including
autologous serum drops.
- Dr. Tseng has obtained the FDA approval
to conduct Phase I clinical trial to determine the safety and
efficacy of Transplantation
of Ex Vivo Expanded Limbal Epithelial Stem Cells for Treating
Limbal Stem Cell Deficiency.
- Channel 7 interview of Dr. Tseng on Amniotic
Membrane Transplantation for Ocular Surface Reconstruction (October
23, 2002).
- Dr. Tseng received Chancellor's Award
from Louisiana State University School of Medicine on November
7, 2002, and gave the lecture entitled "New Strategies of
Ocular Surface Reconstruction". [Honors
and Awards]
|
|
